Hemophagocytic Lymphohistiocytosis Occurring after Induction Chemotherapy in Acute Myelocytic Leukemia.
- Author:
Jung A YOON
1
;
Min Kyung JEON
;
Sun myoung KANG
;
Eunhye OH
;
Seung Hwan SHIN
;
Sichan KIM
;
Je Hwan LEE
Author Information
- Publication Type:Case Report
- Keywords: Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Induction chemotherapy
- MeSH: Bone Marrow; Cyclosporine; Dexamethasone; Diagnosis; Etoposide; Ferritins; Fever; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Hypertriglyceridemia; Induction Chemotherapy*; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid, Acute*; Liver Diseases; Lymphohistiocytosis, Hemophagocytic*; Rare Diseases; Shock
- From:Korean Journal of Medicine 2016;91(1):79-83
- CountryRepublic of Korea
- Language:Korean
- Abstract: Hemophagocytic lymphohistiocytosis (HLH), associated with acute myelocytic leukemia (AML), is a very rare disease. We here report a case of HLH occurring after induction chemotherapy for AML. AML-associated HLH can be triggered by AML itself, by chemotherapeutic agents, or by infectious complications. Our patient developed a high-grade fever of unknown cause, bilateral pulmonary infiltrates, and shock after successful treatment of AML with induction chemotherapy, and had high serum ferritin, hypertriglyceridemia, hypofibrinogenemia, hemophagocytic histiocytes in bone marrow, low natural killer cell activity, and elevated soluble interleukin-2 receptor levels. A diagnosis of HLH was made. Dexamethasone, cyclosporine, and etoposide were given and allogeneic hematopoietic stem cell transplantation was performed. Careful suspicion of HLH may be warranted if a patient experiences fever of unknown etiology, high ferritin levels, and liver dysfunction during AML treatment.
